Inhibitory effects of the ruthenium complex KP1019 in models of mammary cancer cell migration and invasion

Metal-Based Drugs

Volumn 2009, Issue , 2009, Pages

  Bergamo, A ^a,c   Masi, A ^a   Jakupec, M A ^b   Keppler, B K ^b   Sava, G ^a  

^a Callerio Foundation   (Italy)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDAZOLIUM [TETRACHLOROBIS(1H INDAZOLE)RUTHENATE]; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; KP 418; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MODEL; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 70350102566     PISSN: 07930291     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/681270     Document Type: Article

References (23)

1. Clarke M. J., Zhu F., Frasca D. R., Non-platinum chemotherapeutic metallopharmaceuticals Chemical Reviews 1999 99 9 2511 2533
2. Clarke M. J., Ruthenium metallopharmaceuticals Coordination Chemistry Reviews 2003 236 209 233
3. Hartinger C. G., Jakupec M. A., Zorbas-Seifried S., KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients Chemistry and Biodiversity 2008 5 10 2140 2155
4. Schluga P., Hartinger C. G., Egger A., Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP Dalton Transactions 2006 6 14 1796 1802
5. Keppler B. K., Henn M., Juhl U. M., Berger M. R., Niebl R., Wagner F. E., New ruthenium complexes for the treatment of cancer Progress in Clinical Biochemistry and Medicine 1989 10 Berlin, Germany Springer 41 69
6. Kapitza S., Pongratz M., Jakupec M. A., Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells Journal of Cancer Research and Clinical Oncology 2005 131 2 101 110
7. Sava G., Frausin F., Cocchietto M., Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A European Journal of Cancer 2004 40 9 1383 1396
8. Keppler B. K., Rupp W., Juhl U. M., Endres H., Niebl R., Balzer W., Synthesis, molecular structure, and tumor-inhibiting properties of imidazolium trans-bis(imidazole)tetrachlororuthenate(III) and its methyl-substituted derivatives Inorganic Chemistry 1987 26 26 4366 4370
9. Lipponer K.-G., Vogel E., Keppler B. K., Synthesis, characterization and solution chemistry of trans -indazoliumtetrachlorobis(indazole)ruthenate(III), a new anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. Crystal structures of trans -1-methyl- indazoliumtetrachlorobis-(1-methylindazole) ruthenate(III) and its hydrolysis product trans -monoaquatrichlorobis-(1-methylindazole)-ruthenate(III) Metal-Based Drugs 1996 3 5 243 260
10. Cook J. A., Mitchell J. B., Viability measurements in mammalian cell systems Analytical Biochemistry 1989 179 1 1 7
11. Skehan P., Storeng R., Scudiero D., New colorimetric cytotoxicity assay for anticancer-drug screening Journal of the National Cancer Institute 1990 82 13 1107 1112
12. Albini A., Iwamoto Y., Kleinman H. K., A rapid in vitro assay for quantitating the invasive potential of tumor cells Cancer Research 1987 47 12 3239 3245
13. Kueng W., Silber E., Eppenberger U., Quantification of cells cultured on 96-well plates Analytical Biochemistry 1989 182 1 16 19
14. Alley M. C., Scudiero D. A., Monks A., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Cancer Research 1988 48 3 589 601
15. Bradford M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding Analytical Biochemistry 1976 72 1-2 248 254
16. Poliak-Blazi M., Boranic M., Marzan R., Radacic M. A., A transplantable aplastic mammary carcinoma of CBA mice Veterinarski Arhiv 1981 15 99 107
17. Zorzet S., Bergamo A., Cocchietto M., Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes Journal of Pharmacology and Experimental Therapeutics 2000 295 3 927 933
18. Alessio E., Balducci G., Lutman A., Mestroni G., Calligaris M., Attia W. M., Synthesis and characterization of two new classes of ruthenium(III)- sulfoxide complexes with nitrogen donor ligands (L): Na[ trans-RuCl 4 (R 2 S O)(L)] and mer, cis-RuCl 3 (R 2 SO)(R 2 SO)(L). The crystal structure of Na[ trans-RuCl 4 (DMSO)(NH 3)] 2 DMSO, Na[ trans-RuCl 4 (DMSO)(Im)] H 2 O, Me2CO (Im = imidazole) and mer, cis-RuCl 3 (DMSO)(DMS O)(NH 3) Inorganica Chimica Acta 1993 203 2 205 217
19. Kapitza S., Jakupec M. A., Uhl M., Keppler B. K., Marian B., The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells Cancer Letters 2005 226 2 115 121
20. Folgueras A. R., Pends A. M., Snchez L. M., Lpez-Otn C., Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies International Journal of Developmental Biology 2004 48 5-6 411 424
21. Overall C. M., Kleifeld O., Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nature Reviews Cancer 2006 6 3 227 239
22. Alessio E., Mestroni G., Bergamo A., Sava G., Sigel A., Sigel H., Ruthenium anticancer drugs Metal Ions in Biological Systems; Metal Complexes in Tumor Diagnosis and as Anticancer Agents 2004 42 New York, NY, USA Marcel Dekker 323 351
23. Bergamo A., Masi A., Dyson P. J., Sava G., Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound International Journal of Oncology 2008 33 6 1281 1289